References
- Bylund S, Kobyletzki L, Svalstedt M, et al. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. doi:10.2340/00015555-3510
- Mathiesen SM, Thomsen SF. The prevalence of atopic dermatitis in adults: systematic review on population studies. Dermatol Online J. 2019;25(8). doi:10.5070/D3258045124
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi:10.1159/000370220
- Wang J, Ramette A, Jurca M, et al. Association between breastfeeding and eczema during childhood and adolescence: a cohort study. PLoS One. 2017;12(9):e0185066. doi:10.1371/journal.pone.0185066
- Weil C, Sugerman PB, Chodick G, et al. Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide Israeli Healthcare Provider Database. Adv Ther. 2022;39:1–13.
- Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107–114. doi:10.1097/DER.0000000000000034
- Israeli Dermatology Association. Guidelines for the Treatment of Atopic Dermatitis. Israeli Medical Association; 2020.
- Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390–396.
- Kelly KA, Feldman SR. A wealth of new topicals for atopic dermatitis. J Dermatol Treat. 2021;32(6):575. doi:10.1080/09546634.2021.1956770
- Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28(1):3–10. doi:10.1111/exd.13808
- Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e6. doi:10.1016/j.jaad.2016.05.046
- Simpson EL, Paller AS, Boguniewicz M, et al. Crisaborole ointment improves quality of life of patients with mild to moderate atopic dermatitis and their families. Dermatol Ther (Heidelb). 2018;8(4):605–619. doi:10.1007/s13555-018-0263-0
- Israel Central Bureau of Statistics. Characterization and Classification of Geographic Units by the Socio-Economic Level of the Population 2008. Publication No. 1530. Jerusalem, Israel: Israel Central Bureau of Statistics; 2013.
- Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(4):360–366. doi:10.1016/j.anai.2018.12.017
- Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–775. doi:10.1111/bjd.15928